Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs

BACKGROUND: Medications for opioid use disorder such as opioid agonist treatment (OAT, including methadone, buprenorphine) are the gold standard intervention for opioid use disorder (OUD). Persons with OUD have high rates of neurocognitive impairment and psychiatric and substance use disorders, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Travis M., Arnsten, Julia, Olsen, James Patrick, Arias, Franchesca, Cunningham, Chinazo O., Rivera Mindt, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543954/
https://www.ncbi.nlm.nih.gov/pubmed/34689841
http://dx.doi.org/10.1186/s13722-021-00272-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543954/
https://www.ncbi.nlm.nih.gov/pubmed/34689841
http://dx.doi.org/10.1186/s13722-021-00272-4

Ejemplares similares